A Three-point Plan for Digital Delivery
Sam Shah has seen health tech policy up-close and worries that little progress has been made over the past five-years. However, he has a plan…
Health Tech
What do Health Tech Leaders want from the UK General Election Campaign?
As the UK election approaches, whichever party forms the next government will find a health and social care system facing enormous challenges. Highland Marketing asked…
Patients Are Waiting: Speeding Time to Treatment in Rare Disease
Companies are overcoming challenges to develop, launch, and educate on new rare disease medicines and treatment faster. Rare diseases are no longer rare. Every year,…
The Critical Role of Medtech in Healthy Longevity
As the number and proportion of older people in the global population grows, the notion of healthy longevity is commanding attention. Dr Tatiana Sergeenko from…
Health Tech Leaders set out their Priorities for the Incoming UK Government
With less than a month to go until the general election, we spoke to health tech leaders from across the industry to get their views…
Due Care and Attention: Why New Medical Device Regulations need to Balance Protecting Both Patients and Innovation
Patient safety and the prevention of harm is at the centre of all medical advances. And although millions of people receive successful cutting-edge treatments and…
Is ‘Smart Health Tech’ Solving the Right Problems for the NHS?
We need to focus on solving the right problems with technology, and facilitate better conditions, in order to improve smart healthcare adoption at scale in…
Standing Up for Health Tech and SMEs – Shane Tickell’s Vision
As the new chair of the health and social care council at techUK, Shane Tickell talked to Highland Marketing about his determination to support small…
NHS Finances: Cuts get real
The NHS has gone into 2024-5 facing a tough financial situation and both systems and trusts are being asked to make headcount reductions and cuts…
Current State of Drug Development, Clinical Trials, and Precision Measures
Drug research and development can cost up to $6bn per asset and take an average of 13 years from discovery to approval1. In this expensive…